The second-class innovative medical device "Oxidized Low-density Lipoprotein Detection Kit (Immunoturbidimetry)" developed by Goldmag Nanobiotech has been approved for marketing.
Oxidized low-density lipoprotein detection kit (immunoturbidimetric method)
Oxidized low-density lipoprotein (OxLDL) is formed by the oxidation modification of low-density lipoprotein (LDL) under the action of multiple complex factors in the body. The conversion of LDL to OxLDL is a key physiological link in the occurrence and promotion of atherosclerosis (AS). In the early stage of AS lesions, when the vascular endothelium is damaged, monocytes in the blood can pass through the endothelial gap and transform into macrophages under the intima. After LDL is oxidized and modified into OxLDL, it is mainly phagocytosed by binding to scavenger receptors on the surface of macrophages, resulting in lipid accumulation in macrophages and forming foam cells. As the disease progresses, foam cells accumulate to form lipid streaks and even lipid plaques. When lipid plaques are ruptured, platelets adhere and aggregate to form thrombi, which in turn leads to unstable angina, acute myocardial infarction and sudden death. Studies have found that patients with coronary artery disease and atherosclerosis-related diseases (such as stroke, carotid artery plaque, etc.) have higher OxLDL levels, indicating that OxLDL level detection has positive clinical significance in monitoring the condition of coronary heart disease and atherosclerosis-related diseases. Therefore, the immunoturbidimetric detection method of the new blood lipid marker "oxidized low-density lipoprotein" established can be used to assess the risk of cardiovascular events.
This product has received project support from the "Thirteenth Five-Year Plan" National Key R&D Plan "Active Health and Aging Science and Technology Response Key Project" and the "Shaanxi Province 2022 Key R&D Plan" Unveiling Project. The development of a new methodological detection reagent for a new blood lipid marker that is the first in China and the leading in the world is expected to be added to the routine clinical blood lipid detection package.